Security Snapshot

Sagimet Biosciences Inc. - Series A Common Stock, $0.0001 par value per share (SGMT) Institutional Ownership

CUSIP: 786700104

13F Institutional Holders and Ownership History from Q3 2023 to Q3 2026

13F reference period

Q2 2026

Institutions Reporting

122

Shares (Excl. Options)

51.01MFull value: 51,012,704 · shares · 30 Jun 2026

Price

$7.73

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+37,558,737
Value change
+$295,069,135
Number of holders
122
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
72,470,421
SEC-reported price per share
$8.80
Insider filing price
$8.80
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • SGMT - Sagimet Biosciences Inc. - Series A Common Stock, $0.0001 par value per share is tracked under CUSIP 786700104.
  • 122 institutions reported positions in Q2 2026.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 88 to 122 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $69.76MFull value: $69,764,298 · USD · 31 Mar 2026
    to
    $394.29MFull value: $394,288,272 · USD · 30 Jun 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 122 institutions filings for Q2 2026.

Open SEC evidence

Security key

786700104

13F reference period

Q2 2026

13F holders

122

13D/G owners

6

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
6
Security
SGMT
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Commodore Capital LP 7.6% $56,454,458 5,507,752 Commodore Capital LP 30 Sep 2026
BlackRock, Inc. 7.8% $36,726,668 4,751,186 BlackRock, Inc. 30 Jun 2026
BALYASNY ASSET MANAGEMENT L.P. 5.9% $26,978,281 3,626,113 BALYASNY ASSET MANAGEMENT L.P. 30 Jun 2026
AP11 Ltd 4.9% -10% $5,055,597 -$504,198 1,504,642 -9.1% AP11 Limited 24 Jun 2025
Woodline Partners LP 4.8% -44% $10,299,309 -$7,211,088 1,501,357 -41% Woodline Partners LP 30 Sep 2025
Blue Owl Capital Holdings LP 4.3% $4,527,659 1,323,877 Blue Owl Capital Holdings LP 31 Dec 2024
As of 30 Jun 2026, 122 institutional investors reported holding
51.01MFull value: 51,012,704 · shares · 30 Jun 2026
shares of Sagimet Biosciences Inc. - Series A Common Stock, $0.0001 par value per share (SGMT). This represents 70% of the company’s total
72.47MFull value: 72,470,421 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
60%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 9.1% 6,575,788 +722% 0% $50,830,842
Balyasny Asset Management L.P. 5% 3,626,113 0.05% $28,029,853
Woodline Partners LP 4.1% 3,000,652 +200% 0.07% $23,195,040
SILVERARC CAPITAL MANAGEMENT, LLC 4% 2,927,698 2.5% $22,631,106
VANGUARD CAPITAL MANAGEMENT LLC 3.5% 2,566,272 +134% 0% $19,837,283
BVF INC/IL 3.4% 2,500,000 0.49% $19,325,000
Caligan Partners LP 3.4% 2,500,000 0.93% $19,325,000
Affinity Asset Advisors, LLC 3.4% 2,497,864 +188% 0.94% $19,308,489
FEDERATED HERMES, INC. 2.9% 2,086,715 +267085% 0.02% $16,130,307
GREAT POINT PARTNERS LLC 2.8% 2,029,933 3.7% $15,691,382
STATE STREET CORP 2.8% 1,995,092 +1449% 0% $15,422,061
Saturn V Capital Management LP 2% 1,479,918 1.6% $11,439,766
GEODE CAPITAL MANAGEMENT, LLC 2% 1,444,019 +367% 0% $11,165,095
Blue Owl Capital Holdings LP 1.7% 1,260,544 +278% 1.5% $9,744,005
BAKER BROS. ADVISORS LP 1.3% 952,996 0% 0.04% $7,366,659
MILLENNIUM MANAGEMENT LLC 1.3% 937,025 +8.7% 0% $7,243,203
Aberdeen Group plc 1.2% 847,700 0.01% $6,552,721
GOLDMAN SACHS GROUP INC 1% 759,086 +348% 0% $5,867,734
HHLR ADVISORS, LTD. 1% 724,800 0% 0.67% $5,602,704
AMERIPRISE FINANCIAL INC 0.8% 581,217 0% $4,492,807
Vestal Point Capital, LP 0.74% 535,452 0.1% $4,139,044
NORTHERN TRUST CORP 0.65% 468,385 +744% 0% $3,620,617
BOOTHBAY FUND MANAGEMENT, LLC 0.64% 464,095 0.07% $3,587,454
ADAR1 Capital Management, LLC 0.6% 437,500 0.16% $3,381,875
FARALLON CAPITAL MANAGEMENT, L.L.C. 0.57% 415,000 0.02% $3,207,950

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
13
Headline period
Q2 2026
Rows shown
1-13 of 13
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 871,908 $8,602,635 +$2,201,986 $9.88 22
2026 Q2 51,012,704 $394,288,272 +$295,069,135 $7.73 122
2026 Q1 13,353,997 $69,764,298 -$5,892,432 $5.22 88
2025 Q4 14,395,244 $85,220,750 +$8,789,236 $5.92 86
2025 Q3 12,635,689 $86,680,189 +$6,909,222 $6.86 72
2025 Q2 11,676,267 $88,988,335 +$3,493,936 $7.62 67
2025 Q1 13,776,513 $44,920,783 -$15,209,275 $3.26 69
2024 Q4 17,500,774 $78,763,978 -$8,862,770 $4.50 66
2024 Q3 19,656,790 $54,446,688 -$7,224,186 $2.77 63
2024 Q2 20,925,200 $71,568,836 -$7,461,714 $3.42 81
2024 Q1 22,609,183 $122,544,913 +$44,339,223 $5.42 81
2023 Q4 14,445,035 $76,118,157 -$8,948,267 $5.42 51
2023 Q3 11,717,467 $103,113,019 +$103,113,019 $8.80 47
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .